Ftc report patent thickets biologics humira 2023?

Short answer: I don’t see a widely cited FTC report from 2023 titled something like “Patent Thickets Biologics Humira.” There isn’t a well-known, Humira-specific FTC document from 2023. The FTC has discussed patent thickets and biosimilars in various contexts over the years, but not a single 2023 report focused specifically on Humira.

What I can offer right now:
- Quick background: A “patent thicket” is a dense web of overlapping patents that can delay or block entry of competitors. In biologics, companies often rely on broad or many overlapping patents (and related settlements) to extend market protection. Humira (adalimumab) is frequently cited as a high-profile example due to its extensive patent portfolio and the timing of biosimilar entry.
- 2023 landscape (general): Biosimilar competition for Humira intensified as settlements expired or allowed entry and as some patents neared expiration, leading to greater downstream price pressures and market share shifts.

If you want, I can:
- Summarize the general concept of patent thickets in biologics and how Humira illustrates it.
- Help locate a specific FTC document or hearing if you can share a title, link, or allow me to search (note: I’d need browsing capability to fetch the exact document).

Tell me which direction you’d like (overview, or locating a particular FTC source), and I’ll tailor the answer.